Circassia appointed Jean-Jacques Garaud, M.D., to its board of directors...INC Research hired Robert Ryan, Ph.D., as vp of regulatory strategy, consulting, and submissions and Sal Chiovari as chief information officer...Valeant Pharmaceuticals named Ryan Weldon as evp of U.S. dermatology operations and Jason Hanson as evp of U.S. and international businesses...Charlie Morris joined Almac Clinical Technologies as vp of new products and services...The Vaccine and Gene Therapy Institute of Florida added Ted M. Ross, Ph.D., as program director.
Gil Ben-Menachem, Ph.D., is now CEO at OphthaliX...IntelliCell BioSciences added Harry Fisch, M.D., as director of urology...Sequenom named William Welch as president and COO, Dirk van den Boom as evp of R&D, and chief technology officer, and Ronald Lindsay as evp of strategic planning...Virginia Bio appointed Nee-Yin Chou, Ph.D., Alan Connor, Alex Euler, Frank Gilg, Jim Powers, Jason Walsh, and Kenneth Wong, Ph.D., to its board of directors...Bryan M. Reasons is now svp and CFO at Impax Laboratories.
A.P. Pharma hired Mark S. Gelder, M.D., as svp and CMO, Joel Schaedler as vp of market access, and Daniel Martin as vp of marketing...CytoDyn appointed Michael Nobel, Ph.D., and Allan M. Green, M.D., Ph.D., to its board of directors and Michael D. Mulholland as CFO, treasurer, and corporate secretary...Etubics named Gilbert S. Omenn, M.D., Ph.D., to its board of directors...Amgen appointed Robert A. Bradway as chairman of the board and Vance D. Coffman as lead independent director...Maurice Exner, Ph.D., joined IntelligentMDx as vp of research and development.
AtheroNova added Mark K. Wedel, M.D., as svp of clinical affairs and CMO...Third Rock Ventures hired Mark L. Perry and Uday N. Kumar, M.D., as entrepreneurs-in-residence...Oncology Analytics named Robert M. Walton as COO and to its board of directors.
Onyx Pharmaceuticals named N. Anthony Coles, M.D., as chairman of its board of directors...RF Technologies hired Sean Daugherty as svp and general manager for solutions development and sales...Omni Bio Pharmaceutical added Bruce E. Schneider, Ph.D., as CEO...AVEO Oncology appointed Robert Epstein, M.D., to its board of directors...Dale Schenk, Ph.D., is now CEO of Prothena...Icon elected Thomas Lynch as chairman...BioTime hired Jeffrey Janus as vp of sales and marketing.
CorMedix promoted Randy Milby to CEO, Richard M. Cohen to CFO, and Antony E. Pfaffle, M.D., as acting CSO...iBio appointed of Seymour Flug to its board of directors and Andrea Corcoran as svp, finance and strategy...Christopher S. Destro joined Atossa Genetics as vp of sales and marketing...Helix BioPharma named John A. Rogers to its board of directors.
Send your People Announcements to email@example.com